NEW YORK, Aug 17 (Reuters) – Eli Lilly and Co (LLY.N) halted development of an Alzheimer’s drug after it worsened patients’ symptoms in late-stage studies, dealing a fresh blow to the U.S. drugmaker and to research to fight the disease.
The Alzheimer’s setback comes as U.S. regulators raised concerns about using Lilly’s antidepressant Cymbalta to treat chronic . . . → Read More: Lilly halts Alzheimer’s drug as symptoms worsen
A $21-million-dollar infusion from the U.S. Defense Department’s research arm will help a Canadian company set up a manufacturing plant to incubate flu vaccine in tobacco leaves.
Medicago Inc., a Quebec City-based biotech firm, is setting up an 85,000-square-foot facility in Durham, N.C., to manufacture 10 million doses of flu vaccine a month using their new technology. . . . → Read More: Tobacco plants may be new incubator for vaccines for flu – or bio-terrorism
Each year, Canada funds more than $12 billion in research and development to create the ideas that will become the basis for next-generation products.
Sadly for the future of Canadian innovation, the Canadian venture capital industry – whose crucial mission is to finance emerging companies’ commercialization of these ideas into products, jobs and exports – is in . . . → Read More: Funds brighten future of Canadian innovation